Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.
Immune-Onc Therapeutics has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in January 2023.
Immune-Onc Therapeutics's investors include Vivo Capital, Loyal Valley Capital, Blood Cancer United, Inc., Northern Light Venture Capital, Octagon Capital Advisors.
Immune-Onc Therapeutics is headquartered in Palo Alto, United States.
Immune-Onc Therapeutics is a newly established biopharmaceutical company that develops therapeutic antibodies for cancer treatment.
Immune-Onc Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immune-Onc Therapeutics — Funding & Investors." VCBacked, January 5, 2023, https://www.vcbacked.co/company/immune-onc-therapeutics. Accessed July 20, 2026.
VCBacked. (2023). Immune-Onc Therapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/immune-onc-therapeutics
{{cite web |title=Immune-Onc Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/immune-onc-therapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated